A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care.
A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care.
复制标题
DOI：
10.1016/j.ygyno.2009.11.027
复制
发表时间：
2010-03
影响因子：
4.7
通讯作者：
Iasonos A
中科院分区：
文献类型：
--
作者：
Abu-Rustum NR;Zhou Q;Gomez JD;Alektiar KM;Hensley ML;Soslow RA;Levine DA;Chi DS;Barakat RR;Iasonos A
传统上，我们主要依靠最终FIGO阶段来估计子宫内膜癌患者的总体肿瘤学结局。然而，众所周知，其他患者因素可能在结局中发挥同样重要的作用。我们的目的是开发一个临床上有用的列线图，希望提供一个更个性化和准确的估计总生存期（OS）后的主要治疗。使用前瞻性维护的子宫内膜癌数据库，分析了1993-2008年间治疗的1735例患者。收集了通常已知可预测OS的临床特征。对于每例患者，对这5个变量中的每一个进行评分，并计算总分。然后根据列线图确定相应的3年和5年OS概率。中位年龄为62岁（范围：25-96岁）。最终分级包括：G1（471）、G2（622）、G3（634）、缺失（8）。分期包括：IA（501）、IB（590）、IC（141）、IIA（36）、IIB（75）、IIIA（116）、IIIB（6）、IIIC（135）、IVA（7）和IVB（128）。组织学类型包括：腺癌（1376）、癌肉瘤（100）、透明细胞（62）、浆液性（197）。存活者的中位随访时间为29.2个月（0-162.2个月）。诺模图的一致性概率估计为0.746 ± 0.011。使用一个大型的子宫内膜癌数据库，我们开发了一个诺模图的基础上，5个容易获得的临床特征，预测OS具有较高的一致性概率。该列线图结合了FIGO分期以外的其他重要个体化患者变量，以更准确地预测结果。这一新工具可能有助于临床医生在决定辅助治疗和随访时评估患者的风险。
Traditionally we have relied mainly on final FIGO stage to estimate overall oncologic outcome in endometrial cancer patients. However, it is well known that other patient factors may play equally important roles in outcome. Our objective was to develop a clinically useful nomogram in the hope of providing a more individualized and accurate estimation of overall survival (OS) following primary therapy. Using a prospectively maintained endometrial cancer database, 1735 patients treated between 1993–2008 were analyzed. Clinical characteristics commonly known to predict OS were collected. For each patient, points were assigned to each of these 5 variables and a total score was calculated. The corresponding 3- and 5-year OS probabilities were then determined from the nomogram. The median age was 62 years (range, 25–96). Final grade included: G1 (471), G2 (622), G3 (634), missing (8). Stage included: IA (501), IB (590), IC (141), IIA (36), IIB (75), IIIA (116), IIIB (6), IIIC (135), IVA (7), and IVB (128). Histology included: adenocarcinoma (1376), carcinosarcoma (100), clear cell (62), serous (197). Median follow-up for survivors was 29.2 months (0–162.2 months). Concordance probability estimator for the nomogram is 0.746 ± 0.011. Using a large endometrial cancer database we developed a nomogram based on 5 easily available clinical characteristics to predict OS with a high concordance probability. This nomogram incorporates other important individualized patient variables beyond FIGO stage to more accurately predict outcome. This new tool may be useful to clinicians in assessing patients risk when deciding on adjuvant treatment and follow-up.
登录
查看更多内容
影响因子：
10.3
作者：
Panici, Pierluigi Benedetti;Basile, Stefano;Mangioni, Costantino
通讯作者：
Mangioni, Costantino
影响因子：
4.5
作者：
Briganti, Alberto;Gallina, Andrea;Karakiewicz, Pierre I.
通讯作者：
Karakiewicz, Pierre I.
影响因子：
6.2
作者：
Wright, Jason D.;Fiorelli, Jessica;Herzog, Thomas J.
通讯作者：
Herzog, Thomas J.
影响因子：
45.3
作者：
Iasonos, Alexia;Schrag, Deborah;Panageas, Katherine S.
通讯作者：
Panageas, Katherine S.
影响因子：
3.9
作者：
Kim, Mi-Kyung;Kim, Jae Weon;Kang, Soon-Beom
通讯作者：
Kang, Soon-Beom